Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05882279 · OUTCOME

Number of Pharmacists Who Had Provided Patients With the Contents of the Risk Management Plan (RMP) Material

A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan · Source last updated 2024-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to Day 9

What was measured

The NINLARO additional risk minimization measure (aRMM) effectiveness study questionnaire which was intended for pharmacists who instructed the dosing of IRD therapy to patients with relapsed/refractory multiple myeloma (RRMM). This outcome was based on the number of pharmacists who answered "Yes" to question 3; Do you instruct patients that they should take one capsule of NINLARO each time on an empty stomach for RRMM? Here, unit of measure: participants refer to pharmacists.

Analysis population: The final analysis set included all pharmacists who consented to participate in the survey, passed the screening questions, and completed all questions.

Groups in this outcome

Pharmacists in Hospitals Prescribing NINLARO

Pharmacists included in Nikkei Medical Online Panel, active in clinical practice, and with valid contact details who belonged to hospitals and have instructed the dosing of NINLARO (ixazomib) in combination with lenalidomide and dexamethasone (IRD therapy) to patients were selected to participate in the survey.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pharmacists in Hospitals Prescribing NINLARO330

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pharmacists in Hospitals Prescribing NINLARO307Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        307
denoms
  1. counts
    1. group Id
      OG000
      value
      330
    units
    Participants
description
The NINLARO additional risk minimization measure (aRMM) effectiveness study questionnaire which was intended for pharmacists who instructed the dosing of IRD therapy to patients with relapsed/refractory multiple myeloma (RRMM). This outcome was based on the number of pharmacists who answered "Yes" to question 3; Do you instruct patients that they should take one capsule of NINLARO each time on an empty stomach for RRMM? Here, unit of measure: participants refer to pharmacists.
groups
  1. description
    Pharmacists included in Nikkei Medical Online Panel, active in clinical practice, and with valid contact details who belonged to hospitals and have instructed the dosing of NINLARO (ixazomib) in combination with lenalidomide and dexamethasone (IRD therapy) to patients were selected to participate in the survey.
    id
    OG000
    title
    Pharmacists in Hospitals Prescribing NINLARO
param Type
COUNT_OF_PARTICIPANTS
population Description
The final analysis set included all pharmacists who consented to participate in the survey, passed the screening questions, and completed all questions.
reporting Status
POSTED
time Frame
Up to Day 9
title
Number of Pharmacists Who Had Provided Patients With the Contents of the Risk Management Plan (RMP) Material
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice